Cookson Peirce & CO Inc Lineage Cell Therapeutics, Inc. Transaction History
Cookson Peirce & CO Inc
- $1.86 Billion
- Q1 2025
A detailed history of Cookson Peirce & CO Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Cookson Peirce & CO Inc holds 250,000 shares of LCTX stock, worth $220,000. This represents 0.01% of its overall portfolio holdings.
Number of Shares
250,000Holding current value
$220,000% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$43.6 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$7.85 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$5.55 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$4.97 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $149M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...